- Program Target
- Disease Indication
- Blood Cancer
- Development Stage
- IND enabling study
ABL602 is a head-to-tail 2+1 bispecific T cell engager targeting CLL1. ABL602 binds weakly to CD3 in normal tissue, but its binding is greatly potentiated
in tumor microenvironments (TME). ABL602 exhibits anti-tumor activity via CLL1 mediated T cell activation and does not induces cytokines in the
absence of CLL1. ABL602 is expected to be a safer and more effective therapy for AML.